Cowen analyst Joshua Jennings lowered the firm’s price target on Outset Medical to $22 from $33 and keeps an Outperform rating on the shares. The analyst said while they noted persistent macro challenges for its customers, it still raised its 2022 revenue guidance.
Published first on TheFly
